Provided by Tiger Fintech (Singapore) Pte. Ltd.

Outlook Therapeutics, Inc.

1.54
-0.0300-1.91%
Pre-market: 1.570.0300+1.95%04:38 EDT
Volume:288.91K
Turnover:447.93K
Market Cap:49.31M
PE:-0.38
High:1.57
Open:1.57
Low:1.51
Close:1.57
Loading ...

Outlook Therapeutics® Streamlines Operations

THOMSON REUTERS
·
14 Dec 2024

Outlook Therapeutics Inc - to Resubmit Bla Application for Ons-5010 in Q1 2025

THOMSON REUTERS
·
14 Dec 2024

Outlook Therapeutics Inc - Implements Initiatives to Streamline Organization and Reduce Expenses

THOMSON REUTERS
·
14 Dec 2024

BTIG Reaffirms Their Buy Rating on Outlook Therapeutics (OTLK)

TIPRANKS
·
10 Dec 2024

Outlook Therapeutics announces NICE recommendation of LYTENAVA

TIPRANKS
·
04 Dec 2024

Outlook Therapeutics Inc - Enters Strategic Collaboration With Cencora

THOMSON REUTERS
·
04 Dec 2024

Outlook Therapeutics® Announces Nice Recommendation of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet Amd

THOMSON REUTERS
·
04 Dec 2024

Outlook Therapeutics Inc - First Positive Reimbursement Decision Worldwide for Lytenava™; First Launch Anticipated in H1 2025

THOMSON REUTERS
·
04 Dec 2024

BRIEF-Outlook Therapeutics® Announces Executive Leadership Transition

Reuters
·
04 Dec 2024

Outlook Therapeutics Inc - Lawrence Kenyon Appointed Interim CEO of Outlook Therapeutics

THOMSON REUTERS
·
04 Dec 2024

Outlook Therapeutics® Announces Executive Leadership Transition

THOMSON REUTERS
·
04 Dec 2024

Press Release: Outlook Therapeutics(R) Announces Executive Leadership Transition

Dow Jones
·
04 Dec 2024

Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target

MT Newswires Live
·
02 Dec 2024

Outlook Therapeutics Cut to Neutral From Buy by Chardan Capital

Dow Jones
·
02 Dec 2024

Outlook Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Nov 2024

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

Zacks
·
28 Nov 2024